EyeGate Pharma Acquires Jade Therapeutics

EyeGate Pharmaceuticals

EyeGate Pharmaceuticals (NASDAQ:EYEG) has acquired Jade Therapeutics, a closely-held company developing locally administered, polymer-based products designed to treat poorly-served ophthalmic indications.

Jade’s proprietary, cross-linked, bio-erodible hydrogel technology has demonstrated a variety of unique and beneficial characteristics, whether employed alone or as a sustained-release drug-delivery vehicle.

In conjunction with the acquisition, EyeGate will gain a strong research and development team and the co-founders of Jade have been appointed to senior management or consulting roles within EyeGate.

Dr. Barbara Wirostko, a co-founder and CMO of Jade, has joined EyeGate as CMO and Mary Jane Rafii, a co-founder and chief business officer of Jade, has joined in a consulting role to assist with ongoing business development activities.

“The integration of Jade into EyeGate significantly strengthens our market position through the addition of a robust preclinical pipeline that complements EyeGate’s ongoing efforts to develop novel treatments for diseases of the eye,” Stephen From, president and CEO of EyeGate, said in a statement.

Jade’s cross-linked thiolated carboxymethyl hyaluronic acid (CMHA-S) is a modified form of the natural polymer hyaluronic acid, which possesses unique physical and chemical properties such as viscoelasticity and water retention.

The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well suited for treating various ocular surface injuries.

The cross-linked HA product has demonstrated global safety and efficacy in small animals, and is already marketed as a highly efficacious veterinary product by BayerDVM under the Remend brand to treat corneal wounds.

EyeGate intends to initiate a clinical study for Jade’s lead product candidate for corneal epithelial defects in late 2016.

Under the accord, EyeGate will repay Jade’s liabilities of up to $300,000 and will issue 765,728 shares of EyeGate common stock, 90% of which were issued at the closing and 10% of which will be held back for 18 months to satisfy post-closing adjustments or indemnification obligations. The transaction also includes a cash earn-out provision calling for the additional payment of up to $2,164,451, subject to a Jade product receiving FDA marketing approval.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.